Clinical trials

We’re dedicated to breaking boundaries through clinical studies and to finding new and improved ways to treat cancer that deliver better life outcomes for our patients

Clinical trials

Cancer

Protocol : GS-US-587-6156

Cancer

A Phase 2, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Bevacizumab and FOLFIRI Versus Bevacizumab and FOLFIRI in Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC)

Cancer

KEYNOTE-867

Cancer

A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) with or without Pembrolizumab (MK-3475) in Participants with Unresected Stage I or IIA Non-Small Cell Lung Cancer (NSCLC) (KEYNOTE-867)

Cancer

ProstACT-TARGET

Cancer

A Single Arm Trial of External Beam Radiation Therapy (EBRT) in Combination with 177Lu-DOTA-TLX591 Theranostic in Patients with Biochemically Recurrent, Oligometastatic, Prostate Specific Membrane Antigen- Expressing Prostate Cancer

Cancer

KEYNOTE-C93

Cancer

A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab Versus Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in the First-line Setting (KEYNOTE-C93/GOG-3064/ENGOT-en15)

Cancer

THIO-101

Cancer

A Multicenter, Open-Label, Dose-Finding, Phase 2 Study Evaluating THIO Sequenced with Cemiplimab (LIBTAYO®) in Subjects with Advanced Non-Small Cell Lung Cancer (NSCLC)

Cancer

EpimAb - EMB09X101

Cancer

A First-in-human, Phase I Trial of study drug, a Bispecific Antibody Targeting PD-L1 and OX-40 in Patients with Advanced or metastatic Solid Tumours

Breast Cancer

TABITHA

Breast cancer

Heart Disease

Vantage IDE (Enrolment opening soon)

Cardiovascular disease

To evaluate the efficacy and safety of a new valve in patients with severe, symptomatic aortic stenosis.

Heart Disease

AngelMed (Enrolment opening soon)

Cardiovascular Disease

To evaluate a new device in patients with prior acute coronary syndrome.

Heart Disease

Arrowhead (Enrolment opening soon)

Cardiovascular Disease

To evaluate the efficacy and safety on a new drug in participants with Mixed Dyslipidaemia.

Genitourinary Cancer

SAMETA (D5086C00001)

Genitourinary cancer

Cancer

ICP-CL-003030

Cancer

A multi-center open-label, phase I/II clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ICP-192 in patients with advanced solid tumours and FGFR gene alterations

Prostate Cancer

DECREASE

Prostate cancer

Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer detected by PSMA.

Heart Disease

RO-CARDIAC

Heart disease

Can Coronary Artery Calcium Score identified on thoracic planning ct scans be used and actioned to identify patients at high risk of cardiac events: a feasibility study in patients with cancer undergoing radiotherapy (ro-cardiac)

Colorectal Cancer

AMGEN 20190172

Colorectal cancer

A Phase 3 Multicenter, Randomized, Open-label,Active-controlled Study of Sotorasib and Panitumumab Versus Investigator’s Choice (Trifluridine and Tipiracil, or Regorafenib) for the Treatment of Previously Treated Metastatic Colorectal Cancer Subjects with KRAS p.G12C Mutation

Cancer

AMGEN 20190135

Basket – Solid Tumours

A Phase 1b/2, Master Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 (pINN Sotorasib) in Subjects With Advanced Solid Tumours With KRAS p.G12C Mutation

Heart Disease

Victorion Plaque

Cardiovascular Disease, Heart Disease

Heart Disease

Victorion-2 Prevent

Heart Disease, Cardiovascular Disease

To evaluate the impact of a new medication on participants who have established cardiovascular disease and who have had a major adverse cardiovascular event.

Prostate Cancer

CONTACT-02

Prostate cancer

A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with Metastatic Castration-Resistant Pro

Breast Cancer

DESTINY-12

Breast cancer

An Open-Label, Multinational, Multicenter, Phase 3b/4 Study of Trastuzumab Deruxtecan in Patients With or Without Baseline Brain Metastasis With Previously-Treated Advanced/Metastatic HER2-Positive Breast Cancer (DESTINY-Breast12)

Lung Cancer

KRYSTAL-12

Lung cancer

A Randomized Phase 3 Study of MRTX849 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation.

Skin Cancer

Oncobeta EPIC-SKIN (OB-RHSCT-101)

Skin cancer

Efficacy of Personalised Irradiation with Rhenium-SCT Skin Cancer Therapy (SCT) for the treatment of non-melanoma skin cancer; a phase IV, multi-centre, international, open label, single arm study

Prostate Cancer

RADIANT

Prostate cancer

A Phase 4, randomized, open-label, multicenter efficacy and safety study of standard dose of radium-223 dichloride vs. standard doses of novel anti-hormonal therapy (NAH) in patients with bone dominant metastatic castration resistant prostate cancer (mCRPC) progressing on/after one line of NAH.

Liver Cancer

SYS-CAPLIOX (AV-LIVPIBII-01)

Liver cancer

The aim of this study is to assess the efficacy of delivering chemotherapy treatment through the arteries directly to the liver, bypassing the main blood supply throughout the body.

Breast Cancer

HER2 REAL (D9673R00005)

Breast cancer

A Multicountry, Multicentre, Noninterventional Retrospective Study to Describe the Real-world Treatment Patterns and Associated Outcomes in Patients With HER2-positive Unresectable or Metastatic Breast Cancer.

Colorectal Cancer

SEAMARK – C4221022

Colorectal Cancer

A PHASE 2, RANDOMIZED, OPEN-LABEL STUDY OF ENCORAFENIB AND CETUXIMAB PLUS PEMBROLIZUMAB VERSUS PEMBROLIZUMAB ALONE IN PARTICIPANTS WITH PREVIOUSLY UNTREATED BRAFV600E-MUTANT, MSI-H/DMMR METASTATIC COL

Prostate Cancer

Prostact-Select

Prostate cancer

Safety, tolerability, biodistribution, dosimetry and efficacy study of 177Lu-DOTA-TLX591-CHO with best standard of care in patients with PSMA expressing metastatic castration-resistant prostate cancer.

Heart Disease

IONIS

Cardiovascular disease

To evaluate a new medication for the treatment of patients with Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM).

Heart Disease

HighFLO

Heart failure

To evaluate a new mitral valve replacement in patients who moderate-severe or severe mitral regurgitation at a high surgical risk.

Heart Disease

FINEARTS-HF

Heart failure

To evaluate the efficacy and safety of a new drug on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fraction ≥40% (LVEF ≥40%).

Heart Disease

Cardialen AF CL008

Irregular heart beat

Clinical trial of patients with AF and their acceptability of MultiPulse Therapy (low voltage energy used to terminate tachyarrhythmias) prior to their clinically indicated electrophysiology procedure

Heart Disease

ZEUS

Cardiovascular disease

To evaluate if treatment with a new drug reduces the risk cardiovascular disease in patients with established cardiovascular disease, chronic kidney disease and inflammation.

Heart Disease

CATALYST

Atrial fibrillation

Clinical Trial of Atrial Fibrillation Patients Comparing Left Atrial Appendage Occlusion Therapy to Non-vitamin K Antagonist Oral Anticoagulants.

Breast Cancer

AUS-PREDICT

Breast cancer

A Prospective Registry Study to Evaluate the Effect of the DCISionRT Test on Treatment Decisions in Patients with DCIS Following Breast Conserving Therapy.

Heart Disease

Cardialen AF CL007

Atrial fibrillation

Clinical trial of patients with AF and their acceptability of MultiPulse Therapy (low voltage energy used to terminate tachyarrhythmias) prior to their clinically indicated electrophysiology procedure

Heart Disease

VFAHF

Heart failure

To collect data and evaluate the safety of Cardiac Resynchronisation Therapy (CRT) by utilising new techniques and investigational systems for patients in heart failure.

Prostate Cancer

DASL-HiCaP

Prostate cancer

The purpose of this study is to see if a new drug, darolutamide, combined with the current best treatments, can improve outcomes for people with prostate cancer.

Cancer

DYNAMIC-III

Bowel cancer

The aim of this study is to compare treatment informed by ctDNA results to standard care in patients with stage III colon cancer.

Prostate Cancer

CUPID

Prostate cancer

This study will consist of four groups with the initial three groups undergoing dose escalation and the fourth group will be to confirm the optimal dose and imaging conditions.

Lung Cancer

AdvanTIG – BGB-A317-A1217-302

Non-small cell lung cancer

The purpose of the study is to compare progression-free survival between Arm A and Arm B as assessed by investigators according to Response Evaluation Criteria in Solid Tumors Version 1.1.

Prostate Cancer

NINJA

Prostate cancer

The NINJA clinical trial aims to compare two emerging schedules of radiotherapy in the treatment of prostate cancer.

Prostate Cancer

ARANOTE

Prostate cancer

This study will assess the efficacy and safety of darolutamide in combination with standard androgen deprivation therapy (ADT) in patients with metastatic hormone sensitive prostate cancer.

Pancreatic Cancer

MASTERPLAN

Pancreatic cancer

This is a prospective, multicentre randomised, phase II clinical trial, with randomisation 2:1 by minimisation and stratification by tumour stage, planned chemotherapy and institution.

Bladder Cancer

Checkmate-078

Bladder cancer

A Study of Chemo Only Versus Chemo Plus Nivo With or Without BMS-986205, Followed by Post- Surgery Therapy With Nivo or Nivo and BMS-986205 in Patients With MIBC.

Bladder Cancer

BCG + MMC

Bladder cancer

Adding mitomycin C to BCF as adjuvant intravesical therapy for high-risk, non muscle invasive bladder cancer, a randomised phase 3 trial.

Bladder Cancer

KEYPAD

Metastatic kidney cancer

This study is designed to test the safety and potential benefit of adding an existing drug used for bone protection (denosumab) to a new immune stimulating drug (pembrolizumab).

Cancer

DREAM3R

Mesothelioma

The purpose of this study is to see whether adding durvalumab to standard chemotherapy will improve overall survival (OS) in patients with MPM.

Skin Cancer

GENTLER

Skin cancer

The purpose of this trial is to see if a reduced radiotherapy can deliver equivalent treatment response to full dose radiotherapy for patients with skin cancer.

Skin Cancer

BFSCT

Skin cancer

This study aims to clinically validate use of the Baker Skin Field Cancerisation Tool (BSFCT) in people attending St Vincent’s Hospital Melbourne dermatology clinic.

CUPisco

Rare tumors

Phase II targeted therapy or immunotherapy guided by genomic profiling versus platinum based chemotherapy (3C) (after receiving three cycles of platinum based chemotherapy).

Cancer

KEYNOTE-992

Bladder cancer

Assess the antitumor efficacy and safety of pembrolizumab in combination with chemoradiotherapy (CRT) versus CRT alone in participants with muscle-invasive bladder cancer (MIBC).

Breast Cancer

AVATAR

Breast cancer

Stereotactic Radiotherapy for Oligoprogressive ER-positive Breast Cancer (AVATAR).

Breast Cancer

DESTINY-Breast05

Breast cancer

This study will examine the efficacy and safety of trastuzumab deruxtecan compared with trastuzumab emtansine in high-risk patients with residual invasive breast cancer following neoadjuvant therapy.

Skin Cancer

CPOST

Skin cancer

A Randomized, Placebo-Controlled, Double-Blind Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma.

Breast Cancer

CONCERTO

Breast cancer

A comparison of two routinely used skin treatments for women with breast cancer undergoing radiation therapy.

Prostate Cancer

PRIMORDIUM

Prostate cancer

The hypothesis of study is addition of apalutamide to RT+ LHRHa provides superior efficacy in terms of PSMA-PET metastatic progression-free survival-ppMPFS.

Lung Cancer

B8011011

Carcinoma, non-small-cell lung

A Phase 1b/2 Open Label Umbrella Study of Sasanlimab Combined With Anti-Cancer Therapies Targeting Multiple Molecular Mechanisms in Participants With Non-Small Cell Lung Cancer (NSCLC).

Non-Melanoma Skin Cancer

EVOLVE

Non-melanoma Skin Cancer

Evaluation of Oedema and lymphatic function following volumetric modulated arc therapy for non-melanoma extensive skin field cancerisation of the lower limbs.

Prostate Cancer

Telix ENHANCING

Prostate cancer

The purpose of this study is to determine the effect of androgen deprivation therapy, a treatment commonly prescribed in prostate cancer patients, on the effectiveness of medical imaging techniques.

Cancer

CHALLENGE

Colon cancer

A Phase III Study of the Impact of a Physical Activity Program on Disease-Free Survival in Patients With High-Risk Stage II or Stage III Colon Cancer: A Randomized Controlled Trial.

Cancer

ADAPT-MRL

Any cancer

A Long-Term, Prospective and Retrospective, Observational Registry Assessing Technical Data and Clinical Outcomes Following Treatment with MR-Linac.

Lung Cancer

MERMAID-1

Carcinoma, non-small cell lung

The purpose of this study is to assess the efficacy and safety of durvalumab versus placebo following SoC chemotherapy in patients with completely resected stage II-III NSCLC who are MRD+ post surgery

Lung Cancer

MERMAID-2

Carcinoma, non-small cell lung

This is a Phase III double-blind, placebo-controlled study of Durvalumab versus Placebo in patients with stage II-III NSCLC who are MRD-positive following curative intent therapy.

Prostate Cancer

PROPELLER

Prostate cancer

The aim of this study is to determine the safety and tolerability of 64Cu-SARbisPSMA in participants with untreated, confirmed Prostate Cancer.

Prostate Cancer

ENZA-p

Prostate cancer

Investigate the activity and safety of adding Lu-PSMA to enzalutamide in patients with metastatic castrate resistant prostate cancer (mCRPC) not previously treated with chemotherapy.

Dupuytren's Disease

DEPART

Connective tissue disorders

GenesisCare is recruiting patients with Dupuytren’s Disease for a research study called ‘DEPART’.

Heart Disease

PORTICO-NG

Aortic valve stenosis

To evaluate a new valve, the Portico™ NG Transcatheter Aortic Heart Valve, in patients who have symptomatic, severe aortic stenosis and are determined to be at high or extreme surgical risk.

Heart Disease

SUCCOUR MRI SUB-STUDY

Heart failure

To evaluate if treatment with two cardioprotective medications reduces the risk of developing heart failure in participants currently undergoing chemotherapy.

Heart Disease

HighLife

Heart failure

To evaluate a new valve in patients with moderate-severe or severe mitral regurgitation and at high surgical risk.

NDROR

Skin registry

To collect data to evaluate specified outcomes for patients undergoing radiotherapy for skin cancer and inflammatory skin conditions.

Clinical Trial

EXPERT

Breast cancer

A unique opportunity to improve personalised use of radiation therapy in patients with early breast cancer according to their individual risks of local recurrence.